# Integrative pharmacovigilance and AI-based framework uncovers potential drug triggers in juvenile idiopathic arthritis

## TL;DR

This study uses AI and drug safety data to find that lansoprazole may worsen juvenile arthritis, suggesting caution in its use for children at risk.

## Contribution

A novel integrative framework combining pharmacovigilance and AI models to detect drug triggers in juvenile idiopathic arthritis.

## Key findings

- Lansoprazole and aripiprazole showed consistent safety signals across multiple algorithms and models.
- Lansoprazole's effects were validated through transcriptomic data showing immune enrichment in monocytes.
- Drug-disease overlaps and pathways suggest non-antirheumatic drugs may worsen systemic JIA.

## Abstract

Management of juvenile idiopathic arthritis (JIA) relies heavily on long-term pharmacotherapy, yet an increasing number of case reports suggest that some drugs may themselves precipitate or worsen the disease. But systematic methods for detecting these safety signals in pediatric cohorts are still lacking.

We screened 10,012,438 reports from the FAERS database using four disproportionality algorithms (ROR, PRR, EBGM, and BCPNN) to identify potential drug and JIA associations. Three complementary machine learning models were developed, including DMPNN, GCN, and SVM, trained on molecular descriptors, chemical fingerprints, and structural graphs to stratify high-risk compounds. Toxicogenomic profiles were generated using ProTox-3.0, and drug–disease target overlap and pathway enrichment were assessed using the CTD and GeneCards databases. External validation relied on our own newly generated transcriptomic data: (i) our newly generated bulk RNA-seq dataset from 47 individuals (39 JIA patients and 8 controls) and (ii) a multi-center single-cell RNA-seq compendium that combined 21 in-house PBMC profiles obtained at four Chinese pediatric hospitals with 9 publicly available systemic juvenile idiopathic arthritis (sJIA) samples. Two of the in-house sJIA patients were sampled longitudinally, before and one month after IL-6-receptor-inhibitor therapy permitting assessment of treatment-induced transcriptomic shifts. Drug-signature activity was quantified with single-sample GSEA for the bulk data and AddModuleScore for the single-cell data.

We identified drugs with consistent positive signals across all four FAERS-based disproportionality algorithms. Machine learning models (DMPNN, GCN, SVM) independently confirmed 23 high-risk compounds, with 22 overlapping across all models and predicted risk scores >0.60. Among these, lansoprazole and aripiprazole showed strong signals in both pharmacovigilance and DMPNN predictions. Further toxicogenomic analysis revealed immune toxicity patterns overlapping with JIA-related gene targets and pathways. Notably, bulk RNA-seq and single-cell RNA-seq validation demonstrated that lansoprazole signatures were significantly enriched in monocyte from sJIA patients. This multi-level convergence supports the hypothesis that certain non-antirheumatic drugs may aggravate JIA-like inflammation, particularly within the systemic subtype.

In this study, we identify lansoprazole as a likely instigator of systemic juvenile idiopathic arthritis, underscoring that proton-pump inhibitors should be used judiciously in children at autoimmune risk and providing a generalizable playbook for rare-disease pharmacovigilance.